Juan Francisco Rodríguez-Moreno

Author

Hospital Universitario Central de Asturias

Also Known As

J. F. Rodriguez-Moreno, J.F. Rodriguez-Moreno, J.F. Rodríguez-Moreno, Juan Francisco Rodriguez-Moreno, Juan F Rodriguez‑Moreno, Juan F. Rodriguez-Moreno, Juan F. Rodriguez‐Moreno, Juan F. Rodríguez-Moreno, Juan Francisco Rodriguez-Moreno, Juan Francisco Rodríguez-Moreno

Publications

415

Citations

H-Index

Concepts

All Affiliations

Hospital Universitario Central de Asturias Spanish National Cancer Research Centre HM Hospitales Institut Català d'Oncologia Hospital Universitario Ramón y Cajal

About

Juan Francisco Rodríguez-Moreno is an author at Hospital Universitario Central de Asturias specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	126
2	Pathology	3	3	48
3	Pharmacology	3	3	74
4	Health Sciences	2	2	29
5	Immunology	2	2	34

Juan Francisco Rodríguez-Moreno

Publications

199

Citations

H-Index

Page 1

	Year	Citations
Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer: NEODURVARIB Trial. Juan Francisco Rodríguez-Moreno, Guillermo de Velasco, Inmaculada Fernández, Journal of Clinical Oncology Molecular CharacterizationUrologySurgical OncologyCisplatin-based ChemotherapyHrd Tumor	2020	43
PTEN expression and mutations in <i>TSC1</i>, <i>TSC2</i> and <i>MTOR</i> are associated with response to rapalogs in patients with renal cell carcinoma Juan María Roldán‐Romero, Benoit Beuselinck, María Santos, International Journal of Cancer	2019	29
Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel <i>MTOR</i> -Activating Mutation Juan Francisco Rodríguez-Moreno, María Apellániz-Ruiz, Juan María Roldán‐Romero, Journal of the National Comprehensive Cancer Network	2017	20
Cancer immunotherapy does not increase the risk of death by COVID-19 in melanoma patients María González‐Cao, Teresa Puértolas, Eva Muñoz‐Couselo, ImmunologyImmunoeditingPathologyImmunotherapeuticsCancer Patients	2020	19
MEK inhibitor sensitivity in BRAF fusion-driven prostate cancer María Dolores Fenor, Sergio Ruiz‐Llorente, Juan Francisco Rodríguez-Moreno, Clinical & Translational Oncology UrologyMek Inhibitor SensitivityMedicineBrachytherapyCancer Treatment	2022	18
761P Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer. NEODURVARIB trial Juan Francisco Rodríguez-Moreno, Guillermo de Velasco, Carlos Álvarez-Fernández, Annals of Oncology Surgical OncologyUrologyGenitourinary CancerMedicinePharmacology	2020	17
353 Safety and efficacy of tumor infiltrating lymphocytes (TIL, LN-145) in combination with pembrolizumab for advanced, recurrent or metastatic HNSCC Antonio Jimeno, Sophie Papa, Missak Haigentz, Regular and Young Investigator Award Abstracts Neoadjuvant TherapyImmunologyPrior TherapiesPathologyImmunotherapeutics	2020	15
Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy Enrique Grande, Teresa Alonso‐Gordoa, Òscar Reig, ESMO Open	2022	14
Phase II study of dovitinib in first line metastatic or (non resectable primary) adrenocortical carcinoma (ACC): SOGUG study 2011-03. Jesús García-Donás, Susana Hernando Polo, Marta Guix, Journal of Clinical Oncology Surgical OncologyPathologyPhase Ii StudyPharmacotherapyTumor Biology	2014	14
Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03 Jesús García-Donás, Alicia Hurtado, Laia Garrigós, Clinical & Translational Oncology	2023	10

Page 1